XBIT: XBiotech Inc. Stock

by  •  • Comments Off on XBIT: XBiotech Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 244.22
Enterprise Value ($M) 44.19
Book Value ($M) 218.85
Book Value / Share 7.19
Price / Book 1.12
NCAV ($M) 193.95
NCAV / Share 6.37
Price / NCAV 1.26

Profitability (mra)
Return on Invested Capital (ROIC) -0.11
Return on Assets (ROA) -0.10
Return on Equity (ROE) -0.10

Liquidity (mrq)
Quick Ratio 33.07
Current Ratio 33.07

Balance Sheet (mrq) ($M)
Current Assets 201.72
Assets 226.62
Liabilities 7.77
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -37.51
Net Income -24.56
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -18.73
Cash from Investing 61.50
Cash from Financing -0.01

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-07 13G/A Mckenzie W Thorpe 9.68 -2.14
02-07 13G/A Simard John 19.90 27.31
02-07 13G/A Gut Thomas 12.86 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-05-01 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION R
2024-04-24 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION R
2024-03-15 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ Transaction Report pursuant to Sect
2023-11-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2023-08-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2023-05-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-03 9,990 45,324 22.04
2024-05-02 3,457 31,675 10.91
2024-05-01 9,969 37,493 26.59
2024-04-30 9,009 35,230 25.57

(click for more detail)

Similar Companies
VTRS – Viatris Inc. VTYX – Ventyx Biosciences, Inc.
VYGR – Voyager Therapeutics, Inc. XERS – Xeris Biopharma Holdings, Inc.
XLO – Xilio Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io